Progression to type 2 diabetes mellitus after gestational diabetes mellitus diagnosed by IADPSG criteria: Systematic review and meta-analysis

Juan Juan¹, Yiying Sun², Yumei Wei¹, Shuang Wang¹, Geng Song¹, Jie Yan¹, Pengxiang Zhou³,⁴ and Huixia Yang¹*

¹Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China, ²Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, ³Department of Pharmacy, Peking University Third Hospital, Beijing, China, ⁴Institute for drug evaluation, Peking University Health Science Center, Beijing, China

Background: To estimate the progression rates to type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) diagnosed by the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria.

Methods: Systematic review and meta-analysis were conducted by searching Medline, Embase, and Cochrane between January 1, 2010 and December 31, 2021 for observational studies investigating progression to T2DM after GDM. Inclusion criteria were IADPSG-diagnosed GDM, studies with both GDM and controls, postpartum follow-up duration at least one year. Data were pooled by random effects meta-analysis models. Heterogeneity was assessed by I² statistic. The pooled relative risk for incidence of T2DM was 6.43 (95% CI: 3.45-11.96) more likely to develop T2DM in the future compared with controls. For GDM women, the cumulative incidence of T2DM was 12.1% (95% CI: 6.9%-17.3%). The pooled cumulative incidence of T2DM was estimated to be 8% (95% CI: 5-11%) in studies with 1 to 5 years of follow-up and increased to 19% (95% CI: 3-34%) for studies with more than 5 years of follow-up. Women with IADPSG-diagnosed GDM had a higher risk of developing pre-diabetes (including impaired fasting glucose and/or impaired glucose tolerance) than controls. Meta-regression analysis showed that the study effect size was not significantly associated with study design, race, length...
of follow-up, and maternal age (P>0.05). Overall, the studies had a relatively low risk of bias.

**Conclusions:** Women with IADPSG-diagnosed GDM have higher risk of developing T2DM and pre-diabetes. The risk of T2DM in GDM women are higher with longer follow-up duration. Our results highlight the importance of promoting postpartum screening and keeping health lifestyle as well as pharmacological interventions to delay/prevent the onset of T2DM/pre-diabetes in GDM women.

**Systematic review registration:** https://www.crd.york.ac.uk/prospero, identifier (CRD42022314776)

**KEYWORDS**
gestational diabetes mellitus, type 2 diabetes mellitus, IADPSG criteria, systematic review, meta-analysis

**Introduction**

Gestational diabetes mellitus (GDM) is an established risk factor for developing type 2 diabetes mellitus (T2DM) in later life. Previous meta-analysis has highlighted a nearly 10-fold higher risk of T2DM in women with GDM compared with controls (1). In 2010, the International Association of Diabetes and Pregnancy Study Group (IADPSG) proposed new diagnostic criteria for GDM using a one-step strategy with 75g oral glucose tolerance test (OGTT) during 24–28 weeks of gestation, and the diagnostic thresholds for GDM were identified as one or more of plasma glucose values equaling or exceeding 5.1 mmol/L (92 mg/dl), 10.0 mmol/L (180 mg/dl), and 8.5 mmol/L (153 mg/dl) at fasting, 1-hour, and 2-hour after 75g OGTT (2). This was the first evidence-based, large-scale diagnostic criteria based on glucose levels associated with adverse pregnancy outcomes in the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study (3). The IADPSG diagnostic criteria marked a milestone in the history of GDM diagnostic criteria, and many international organizations, including American Diabetes Association (ADA) (4), World Health Organization (WHO) (5), the International Federation of Gynecology and Obstetrics (6) et al. advocated the use of 75g OGTT during 24–28 weeks of gestation as the diagnostic test and the new cutoff values recommended by IADPSG as GDM diagnostic criteria.

The application of this landmark IADPSG diagnostic criteria led to a rise in the prevalence of GDM globally, which contribute to a rise in the healthcare and economic burden worldwide (7–10). Due to changes in GDM diagnosis criteria, although the IADPSG criteria had been implemented for almost 12 year, previous systematic review and meta-analysis evaluating progression to T2DM after GDM did not distinguish different kinds of diagnosis criteria, and no available meta-analysis reported the risk of T2DM and pre-diabetes after GDM diagnosed by IADPSG criteria. As is well-known, lifestyle and pharmacological intervention could prevent or delay progression to T2DM in women with previous GDM (11). Therefore, there is an urgent need to evaluate more recent evidence on the risk of progression to T2DM in women with GDM diagnosed by IADPSG criteria. This systematic review and meta-analysis aimed to investigate progression to T2DM in women with GDM diagnosed by IADPSG criteria compared with controls.

**Methods**

This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. The protocol of the study had been registered on the International prospective register of systematic reviews (PROSPERO) (registration number: CRD42022314776).

**Search strategy**

We conducted a comprehensive literature search using Medline, Embase, the Cochrane Library, Scopus, AJOL, and Hinari for observational studies investigating progression to T2DM after GDM diagnosed by IADPSG criteria published between January 1, 2010 and December 31, 2021. We chose 2010 as the start date because the IADPSG GDM diagnostic criteria was released in 2010. The search strategy included keywords, medical subject headings (MeSH), and free text words covering “gestational diabetes mellitus” and “type 2 diabetes mellitus”,...
and was restricted to studies published in English and conducted on humans. The search strategy was shown in the Supplementary Material.

Study selection

Two authors (J.J. and YY.S.) independently reviewed the titles and abstracts to identify all potentially relevant studies. All duplicate records were removed. Full text of the relevant studies were obtained and screened in details according to the following predefined eligibility criteria: GDM diagnosed by IADPSG criteria, duration of postpartum follow-up at least one year, studies with both GDM women and controls (pregnant women without GDM). All reference lists from relevant reviews were hand searched for additional eligible studies. All conference proceedings, guidelines, consensus, opinions, protocols, dissertations, case series, qualitative studies, commentaries, editorials, perspectives, and letters were excluded. Disagreements between the two authors were resolved by third party consultation. The literature review and study selection process were summarized in a PRISMA flowchart (Figure 1).

Data extraction

Two authors (J.J. and YY.S.) independently extracted information from the included studies according to the Cochrane Handbook guidelines, and findings were reported according to the PRISMA and MOOSE guidelines. The extracted data was exported to an excel sheet detailing the authors’ name, country of origin of the study, year of publication, study design, sample size (including the number of GDM and control), length of follow-up, participants’ age, race, diagnostic criteria for T2DM, incidence of T2DM and prediabetes (including impaired fasting glucose[IFG] and/or impaired glucose tolerance[IGT]) among GDM and control, etc. Disagreements were settled by consensus among all authors.

Study quality assessment and risk of bias

The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of non-randomized studies (12). The scale for cohort studies consisted of three categories: Selection, Comparability, and Outcome. Based on the guideline of the scale, a cohort study could be awarded a maximum of one star for each item of the Selection and Outcome categories and a maximum of two stars for the category of comparability. Totally, a study could be awarded from zero up to nine stars. Publication bias was assessed by the Begg’s and Egger’s tests and funnel plots diagram for asymmetry.

Statistical analysis

The pooled relative risk for the incidence of T2DM and prediabetes between participants with GDM and controls was
estimated. Data were pooled by random effects meta-analysis models with the Review Manager (version 5.4; Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) using the DerSimonian-Laird method. In studies which no cases of T2DM and pre-diabetes was reported in any of the groups, a continuity correction was applied using the default value of 0.5 to avoid division by zero. Heterogeneity among the included studies was assessed by I² statistic, and graphically represented using forest plot diagram. Pre-specified subgroup analyses by race and length of study follow-up was performed to explore potential sources of heterogeneity among studies. Meta-regression models were fitted to estimate the effects of study heterogeneity and investigated the cumulative risk of developing T2DM by study length of follow-up. Sensitivity analysis were conducted by recalculating the pooled estimate with a named study removed at a time to estimate the effect of each individual study on the overall pooled estimate.

Results

Study selection

The initial comprehensive literature search identified 8152 records. After exclusion of duplicates, 7807 articles were screened, of which 373 studies were selected for further detailed review using the full text. One study retrieved from the reference lists of previous relevant reviews were also included. Finally, six studies, including a total of 61932 individuals (21978 women with GDM and 39954 controls) fulfilled all the eligibility criteria and were included in the meta-analysis. The study selection process was summarized in Figure 1.

Study quality assessment

All six included studies underwent quality assessment with NOS scale received a total of six to eight stars, suggesting that the risk of bias is relatively low. A summary of the study quality assessment was shown in the Supplementary Material-STable 1.

Study characteristics

All studies included in this systematic review and meta-analysis were observational studies, of which three were prospective cohorts and the other three were retrospective cohorts. One study was a multi-centered study including ten field centers (13), the rest five studies were conducted in Canada, Australia, United Arab Emirates, Pakistan, and Japan, respectively (14–18). The six included studies had different lengths of follow-up, ranged from 1.3 to 11.4 years. A summary of study characteristics of the included studies was presented in Table 1.

Meta-analysis

The meta-analysis of the six studies evaluated a total of 61932 participants (21978 women with GDM and 39954 controls). Among the participants, 1342 women from the GDM group subsequently developed T2DM during postpartum follow-up, while 329 women progressed to T2DM in the control group. The pooled relative risk of developing T2DM in the GDM group was 6.43 (RR=6.43, 95% CI:3.45-11.96) compared with controls (Figure 2). Significant heterogeneity was seen in the overall effect estimate (I² = 88.2%, P<0.001) (Figure 2). In addition, women who had GDM were 3.69 times (RR=3.69, 95% CI:2.70-5.06) more likely to develop pre-diabetes (including IFG and/or IGT) than controls (Figure 3).

The risk of T2DM were assessed by pre-specified subgroup analysis based on study length of follow-up. Studies were classified by their length of follow-up into two groups: 1-5 years and more than 5 years. The estimated pooled relative risk of developing T2DM was 4.38 (95% CI:1.18-16.34) for studies with postpartum follow-up of 1-5 years, while for those with follow-up of more than five years, the pooled relative risk was 12.47 (95% CI:3.10-50.08). The pooled relative risks were not statistically significantly different between subgroups (P=0.28) (Figure 4). The relative risk of T2DM was also assessed by subgroup analysis based on race and the difference in pooled relative risks by subgroup was not statistically significant (P=0.67).

Further meta-regression analyses showed that the study effect size was not significantly associated with study design, race, length of follow-up, and maternal age (P>8%92C3:0.05) (Table 2). Overall, in women with GDM, the cumulative incidence of T2DM and pre-diabetes were 12.1% (95% CI: 6.9%-17.3%) and 25.5% (95% CI: 4.1%-46.8%), respectively. The pooled cumulative incidence of T2DM was estimated to be 8% (95% CI: 5%-11%) in women with GDM in studies with 1 to 5 years of follow-up, increasing to 19% (95% CI: 3%-34%) for studies with more than 5 years of follow-up (Table 3).

Publication bias and sensitivity analysis

No indication of publication bias was detected among the included studies, with both Begg’s and Egger’s tests being statistically non-significant (P=0.71 and P=0.76, respectively). No apparent asymmetry was observed in the funnel plots diagram of the six studies included in the meta-analysis (Supplementary Material-SFigure 1).
| Author          | Year | Country              | Study design     | Participants' age | Race          | GDM sample size | Control Sample Size | Total Sample Size | Follow-up (years) | T2DM diagnostic criteria | T2DM/ GDM | T2DM/ Control | Pre-diabetes/ GDM | Pre-diabetes/ Control |
|-----------------|------|----------------------|------------------|-------------------|--------------|----------------|-------------------|-------------------|-------------------|------------------------|------------|---------------|---------------------|-----------------------|
| Hiersch et al.  | 2021 | Canada               | retrospective cohort | 30.55             | Mixed        | 20513          | 34848             | 55361             | 4.4               | Diabetes Canada 2018 clinical practice guidelines | 1132/20513 | 244/34848      | –                   | –                     |
| Wood et al.     | 2021 | Australia            | prospective cohort |                  | White        | 172            | 122              | 294               | 2.5               | WHO, ADA               | 11/172     | 2/122         | 16/172              | 1/122                 |
| Bayoumi et al.  | 2021 | United Arab Emirates | retrospective cohort | 38.7             | Non-white    | 362            | 833              | 1195              | 9                 | ADA                    | 96/362     | 9/833         | 171/362             | 145/833               |
| Aziz et al.     | 2018 | Pakistan             | prospective cohort |                  | Non-white    | 78             | 89               | 167               | 2                 | HbA1C ≥6.5%; or FBG ≥126 mg/dL (7.0 mmol/L); or 2-h blood glucose ≥200 mg/dL (11.1 mmol/L) during an OGTT; or A random plasma glucose ≥200 mg/dL (11.1 mmol/L) | 11/78      | 0/89         | 3/78                | –                     |
| Lowe et al.     | 2018 | Multi-country including 10 field centers | prospective cohort |                  | Mixed        | 663            | 3946             | 4609              | 11.4              | ADA                    | 71/663     | 63/3946       | 275/663             | 728/3946              |
| Kugishima et al.| 2018 | Japan                | retrospective cohort |                  | Non-white    | 190            | 116              | 306               | 1.3               | WHO                    | 21/190     | 11/116        | –                   | –                     |
Sensitivity analysis was conducted, in which a named study was removed, and the others were analyzed, the pooled estimate remained close to the overall estimate and without apparent fluctuation, indicating that no individual study had a large influence on pooled estimate.

Discussion

Main findings

The results of the systematic review and meta-analysis demonstrated that women who had GDM diagnosed by IADPSG criteria were 6.43 times (RR=6.43, 95% CI:3.45-11.96) more likely to develop T2DM in the future compared with controls. In women with previous GDM, the cumulative incidence of T2DM was 12.1% (95% CI: 6.9%-17.3%), while the pooled cumulative incidence of T2DM was estimated to be 8% (95% CI: 5-11%) in studies with 1 to 5 years of follow-up and increased to 19% (95% CI: 3-34%) for studies with more than 5 years of follow-up. Women with IADPSG-diagnosed GDM had 3.69 times (RR=3.69, 95% CI:2.70-5.06) higher risk of developing pre-diabetes than controls. Meta-regression analysis showed that the study effect size was not significantly associated with study design, race, length of follow-up, and maternal age (P>0.05). Overall, the studies had a relatively low risk of bias.

Comparison with previous studies

In this systematic review and meta-analysis, we included evidence from the most recent studies and specified GDM diagnostic criteria to IADPSG to estimate the risk of developing T2DM after GDM. The findings of our study suggested a higher risk of T2DM and pre-diabetes in women with GDM than controls, similar trends reported by previous systematic reviews and meta-analysis (1, 19, 20). However, previous studies conducted by Kim et al. published in Diabetes Care in 2002 (20), Bellamy et al. published in the Lancet in 2009 (19), and Vounzoulaki et al. published in the BMJ in 2020 (1) evaluated studies published between 1965-2001, 1960-2009 and 2000-2020, respectively, which involved GDM women diagnosed by different diagnostic criteria, thus could have led to different overall risk of subsequent T2DM in women with GDM. The systematic review and meta-analysis conducted by Bellamy et al. (19) and Vounzoulaki et al. (1) reported a 7.43 times (RR=7.43, 95% CI:4.79-11.51) and 9.51 times (RR=9.51, 95% CI:7.14-12.67) higher risk of developing T2DM in women with previous GDM than controls, respectively, which was higher than our findings. The systematic review conducted by Kim et al. (20) demonstrated that the cumulative incidence of T2DM increased markedly in the first 5 years after delivery and appeared to plateau after 10 years, which was inconsistent with our results that the risk of T2DM was higher in studies with more than 5 years of follow-up than 1 to 5 years in women with previous GDM.
As the definition of GDM in studies conducted by previous systematic reviews and meta-analysis was all hyperglycemia first detected at any time during pregnancy, which also included women with pre-existing diabetes mellitus who were not identified prior to pregnancy and did not distinguish between diabetes in pregnancy and GDM. Women with pre-gestational diabetes mellitus indicated the underlying T2DM short-term after delivery. Therefore, the previous study found that the incidence of T2DM increased markedly in the first 5 years after delivery. Unlike previous systematic reviews, the definition of GDM we used in this study was diabetes first diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes prior to gestation (4).

Furthermore, the GDM diagnostic criteria had been constantly evolving during the past few decades, with the diagnostic strategy evolved from “two-step strategy” (GDM was diagnosed by stepwise approach: Step 1: 50g fasting plasma glucose test [GCT]; Step 2: For pregnant women whose 1-hour glucose value of 50g GCT is equal to or greater than 7.8 mmol/L [140 mg/dl], 75g/100g OGTT was conducted) (21, 22) to “one-step strategy” (GDM was diagnosed by 75g OGTT during 24-28 gestational week, and the diagnostic thresholds for GDM were identified as one or more of plasma glucose values equaling or exceeding 5.1 mmol/L [92 mg/dl], 10.0 mmol/L [180 mg/dl], and 8.5 mmol/L [153 mg/dl] at fasting, 1-hour, and 2-hour after 75g OGTT) (2); the cut-off value of fasting plasma glucose (FPG) for GDM evolved from 5.8 mmol/L (National Diabetes Data Group [NDDG], 1979) (21) to 5.3 mmol/L (Carpenter and Coustan, 1982) (22), and then to 5.1 mmol/L (IADPSG, 2010) (2); the diagnostic thresholds evolved from two or more abnormalities (21, 22) to one or more abnormalities (2). The newly released IADPSG criteria is the first scientific based diagnostic criteria predominantly based on HAPO study (3) and marked a milestone in the history of GDM diagnostic criteria. The IADPSG criteria had been advocated by many international organizations, including ADA (4), WHO (5), and the international Federation of Gynecology and Obstetrics (6). Studies had shown that the prevalence of GDM had increased significantly by implementation of IADPSG diagnostic criteria and more pregnant women with milder degrees of gestational hyperglycemia were diagnosed as GDM, which provided an opportunity for earlier detection and effective lifestyle intervention of milder GDM to prevent adverse pregnancy outcomes (7–9). We specified GDM diagnostic criteria to IADPSG in this meta-analysis. Therefore, the previous

### TABLE 2 Results of meta-regression models.

| Study level variables | Coefficient (95%CI) | P values | $I^2$ (%) |
|----------------------|---------------------|----------|----------|
| Study design         |                     |          |          |
| Retrospective cohort study | 0.84 (0.04, 16.90) | 0.884    | 90.37    |
| Prospective cohort study | Ref.               |          |          |
| Race                 |                     |          |          |
| White                | 1.01 (0.02, 66.58)  | 0.992    | 92.55    |
| Non-white            | 0.54 (0.00,185.31)  | 0.757    | 92.55    |
| Mixed                | Ref.                |          |          |
| Length of follow-up (mean) | 1.51 (0.84, 1.57)  | 0.277    | 89.95    |
| Age (mean)           | 1.08 (0.75, 1.55)   | 0.589    | 89.58    |

![FIGURE 4](Relative risk of T2DM in women with GDM compared with controls based on study length of follow-up.)
women with previous GDM over 10 years of follow-up reduce progression to diabetes by 35% and 40%, respectively, in centers, intensive lifestyle intervention and metformin could be effective. A randomized controlled clinical trial conducted at 27 clinical centers showed healthy eating patterns (36). According to subsequent T2DM risk after GDM was significantly lower in women who following healthy eating patterns (27, 28). The increased risk of both GDM and T2DM, suggesting that these conditions might have a shared genetic background (27, 28). The genetic predisposition for GDM in women with GDM diagnosed by IADPSG criteria still had a higher risk of subsequent progression to T2DM and pre-diabetes. Genetic predisposition for GDM in women with IADPSG-diagnosed GDM, with a relatively large total number of individuals, and postpartum follow-up duration ranging from 1.3 to 11.4 years. As the diagnostic criteria of GDM had changed over the past years, this meta-analysis provided up-to-date results using the specific IADPSG criteria. Nevertheless, several limitations should also be considered. Owing to limited availability of studies evaluating the risk of progression to T2DM in women with GDM diagnosed by IADPSG criteria, only a few studies fulfilled all the eligibility criteria and were included in this meta-analysis, resulting in inclusion of a relatively small sample size. Therefore, we were unable to investigate the progression to T2DM after GDM in certain subgroups, which could have been a cause of heterogeneity among studies. Furthermore, we were unable to identify the main sources of heterogeneity in our analysis, and a more in-depth analysis could have been performed if individual patient level data were available. In addition, the IADPSG criteria was released in 2010 and many of the women might have not been developed T2DM at the time of assessment. Therefore, more high-quality studies with longer and complete follow-up are needed to accurately evaluate the progression to T2DM in women with GDM.

### Conclusions

In conclusion, our systematic review and meta-analysis showed that women with GDM diagnosed by IADPSG criteria had higher risk of developing T2DM and pre-diabetes than controls. The risk of T2DM in women with previous GDM was higher in studies with more than 5 years of follow-up than 1 to 5 years.
years. Our results highlight the importance of promoting postpartum screening and keeping health lifestyle, including physical exercise and balanced diet, as well as pharmacological interventions to delay or prevent the onset of T2DM/pre-diabetes in women with GDM.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**Author contributions**

HY and JJ conceived and designed the study. JY and YS conducted the study selection and data extraction. JY and PZ conducted the study quality assessment and statistical analysis. JJ wrote the manuscript. HY, YW, SW, GS, and JY reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

**Funding**

This research was funded by the Youth Program of National Natural Science Foundation of China (82003528), the National High Level Hospital Clinical Research Funding ("Star of Outlook" Scientific Research Project of Peking University First Hospital) (22cz020301-4803014), the National Key Research and Development Program of China (2021YFC2700700).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.1012244/full#supplementary-material

**References**

1. Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ (2020) 369:m1361. doi: 10.1136/bmj.m1361

2. Weinert LS. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy: comment to the international association of diabetes and pregnancy study groups consensus panel. Diabet Care (2010) 33(7):e97. doi: 10.2337/dc10-0544

3. Study Cooperative Research Group HAPO, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med (2008) 358(19):1991–2002. doi: 10.1056/NEJMoa0707943

4. American Diabetes Association. 2. classification and diagnosis of diabetes: Standards of medical care in diabetes-2022. Diabetes Care (2022) 45(Suppl 1):S17–38. doi: 10.2337/dc22-S002

5. WHO guidelines approved by the Guidelines Review Committee. Diagnostic criteria and classification of hyperglycemia first detected in pregnancy. Geneva: World Health Organization (2013).

6. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The international federation of gynecology and obstetrics (FIGO) initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. (2015) 131 Supp 3:S173–211. doi:10.1002/s0012-7292 (15)30033-3

7. Sacks DA, Hadden DR, Mareh M, Deenochanawong C, Dyer AR, Metzger BE, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the hyperglycemia and adverse pregnancy outcome (HAPO) study. Diabetes Care (2012) 35(3):526–8. doi: 10.2337/dc11-1641

8. O’Sullivan EP, Avolos G, O’Reilly M, Dennyd MC, Gaffney G, Dunne F, et al. Atlantic Diabetes in pregnancy (DIP): the prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria. Diabetologia. (2011) 54(7):1670–5. doi:10.2337/a10-2150-4

9. Juan J, Yang H. Prevalence, prevention, and lifestyle intervention of gestational diabetes mellitus in China. Int J Environ Res Public Health (2020) 17(24):9517. doi:10.3390/ijerph17249517

10. Juan J, Yang H, Su R, Kapur A. Diagnosis of gestational diabetes mellitus in China: Perspective, progress and prospects. Maternal-Fetal Med (2019) 1(1):31–7. doi:10.1097/FMF.0000000000000009

11. Minooee S, Ramezani Tehrani F, Rahmati M, Mansournia MA, Azizi F. Diabetes incidence and influencing factors in women with and without gestational diabetes mellitus: A 15-year population-based follow-up cohort study. Diabetes Res Clin Pract (2017) 128:24–31. doi:10.1016/j.diabres.2017.04.003

12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. (2010) 25(9):603–5. doi:10.1007/s10654-010-9491-z

13. Lowe WL Jr, Scholten DM, Lowe LP, Kuang A, Nodzenski M, Talbot O, et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA. (2018) 320(10):1005–16. doi:10.1001/jama.2018.11628

14. Hiersch L, Shah BR, Berger H, Geary M, McDonald SD, Murray-Davis B, et al. Oral glucose tolerance test results in pregnancy can be used to individualize the risk of future maternal type 2 diabetes mellitus in women with gestational diabetes mellitus. Diabetes Care (2021) 44(8):1860–7. doi:10.2337/dc21-0659

15. Wood AJ, Boyle JA, Barr ELM, Barzi F, Hare MJL, Tithum A, et al. Type 2 diabetes after a pregnancy with gestational diabetes among first nations women in...
Australia: The PANDORA study. *Diabetes Res Clin Pract* (2021) 181:109092.
doi: 10.1016/j.diabres.2021.109092

16. Bayoumi RAL, Khamis AH, Tahlaq MA, Elgergawi TF, Harb DK, Hazari KS, et al. Utility of oral glucose tolerance test in predicting type 2 diabetes following gestational diabetes: Towards personalized care. *World J Diabetes*. (2021) 12 (10):1778–88. doi: 10.4239/wjd.v12i10.1778

17. Aza S, Munim TF, Fatima SS: Post-partum follow-up of women with gestational diabetes mellitus: effectiveness, determinants, and barriers. *J Matern Fetal Neonatal Med* (2018) 31(12):1607–12. doi: 10.1080/14767058.2017.1321630

18. Kugishima Y, Yasuhi I, Yamashita H, Sugimi S, Umezaki Y, Suga S, et al. Risk factors associated with the development of postpartum diabetes in Japanese women with gestational diabetes. *BMC Pregnancy Childbirth* (2018) 18(1):19.
doi: 10.1186/s12884-017-1654-4

19. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet* (2009) 373 (9677):1773–9. doi: 10.1016/S0140-6736(09)60731-5

20. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care* (2002) 25(10):1862–8.
doi: 10.2337/diacare.25.10.1862

21. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* (1979) 28(12):1039–57.
doi: 10.2337/diab.28.12.1039

22. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol* (1982) 144(7):768–73. doi: 10.1016/0002-9378(82)90349-0

23. Hovinen E, Lahit J, Klemetti MM, Bergman PH, Räikkönen K, Orho-Melander M, et al. Genetic risk of type 2 diabetes modifies the effects of a lifestyle intervention aimed at the prevention of gestational and postpartum diabetes. *Diabetologia* (2022) 55(8):1291–301. doi: 10.1007/s00125-022-05372-7

24. Rhee SY, Kim JY, Woo JT, Kim HS, Kim SH. Familial clustering of type 2 diabetes in Korean women with gestational diabetes mellitus. *Korean J Intern Med* (2010) 25(3):269–72. doi: 10.3904/kjim.2010.25.3.269

25. Mao H, Li Q, Gao S. Meta-analysis of the relationship between common type 2 diabetes risk gene variants and gestational diabetes mellitus. *PloS One* (2012) 7(9):e45882. doi: 10.1371/journal.pone.0045882

26. Pu J, Zhao B, Wang EJ, Nimbal V, Osmundson S, Kunz L, et al. Racial/Ethnic differences in gestational diabetes prevalence and contribution of common risk factors. *Paediatr Perinat Epidemiol* (2015) 29(5):436–43. doi: 10.1111/ ppe.12209

27. Krishnan M, Murphy R, Okesene-Gafa KAM, Ji M, Thompson JMD, RS T, et al. The specific CREB5 rs373863682 allele protects against gestational diabetes mellitus in māori and pacific women with obesity. *Diabetologia* (2020) 63 (10):2169–76. doi: 10.1007/s00125-020-04520-8

28. Shen Y, Yu Y, Li Y, Gai X, Wan G, Zhang P, et al. Genetic determinants of gestational diabetes mellitus: a case-control study in two independent populations. *Acta Diabetol* (2020) 57(7):845–52. doi: 10.1007/s00592-020-1485-w

29. Moon JH, Kwak SH, Jang HC. Prevention of type 2 diabetes mellitus in women with previous gestational diabetes mellitus. *Korean J Intern Med* (2017) 32 (1):26–41. doi: 10.3904/kjim.2016.209

30. Minsart AF, Vander Maelen A, Fontaine V, Kirkpatrick C. Social, medical and self-perceived factors influencing postpartum screening of diabetes after gestational diabetes. *J Obstet Gynaecol* (2014) 34(1):8–12. doi: 10.1109/ AOG.000000000001467

31. Almario CV, Ecker T, Moroz LA, Bucovetsky I, Berghella V, Baxter JK. Obstetricians seldom provide postpartum diabetes screening for women with gestational diabetes. *Am J Obstet Gynecol* (2008) 198(5):528.e1–5. doi: 10.1016/j.ajog.2007.11.001

32. Chang Y, Chen X, Cui H, Zhang Z, Cheng L. Follow-up of postpartum women with gestational diabetes mellitus (GDM). *Diabetes Res Clin Pract* (2014) 106(2):236–40. doi: 10.1016/j.diabres.2014.08.020

33. Sunny SH, Malhotra R, Ang SB, Lim CSD, Tan YSA, Soh YMB, et al. Facilitators and barriers to post-partum diabetes screening among mothers with a history of gestational diabetes mellitus–a qualitative study from Singapore. *Front Endocrinol (Lausanne)*. (2020) 11:602. doi: 10.3389/fendo.2020.00602

34. Daly B, Toulis KA, Thomas N, Gokhale K, Martin J, Webber J, et al. Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: A population-based cohort study. *PLoS Med* (2018) 15(1):e1002488. doi: 10.1371/journal.pmed.1002488

35. Tobias DK, Hu FB, Chavarro J, Rosner B, Mozaffarian D, Zhang C. Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. *Arch Intern Med* (2012) 172(20):1566–72. doi: 10.1001/archinternmed.2012.3747

36. Arora VR, Christophi CA, Edelstein SL, Zhang P, Herman WH, Barrett-Connor E, et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the diabetes prevention program study–10-year follow-up. *J Clin Endocrinol Metab* (2015) 100(4):1646–53. doi: 10.1210/jc.2014-3761

37. Ratner RE, Christophi CA, Matzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* (2008) 93 (12):4774–9. doi: 10.1210/jc.2008-0772